Literature DB >> 10391102

Development of erythrocytosis in the course of essential thrombocythemia.

R Jantunen1, E Juvonen, E Ikkala, K Oksanen, P Anttila, T Ruutu.   

Abstract

Erythrocytosis is not a feature of essential thrombocythemia (ET); this is the most important difference between ET and polycythemia vera (PV). Transformation of ET to PV has only rarely been described. We have reviewed the blood cell counts of 170 ET patients with a median follow-up of 63 months (range 11-313). Eleven of 170 patients (6.5%) developed erythrocytosis at a median of 29 months (range 12-138) after the diagnosis of ET. According to the present results, the development of erythrocytosis in patients with ET is not a rare phenomenon.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10391102     DOI: 10.1007/s002770050505

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  4 in total

Review 1.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

2.  The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

Review 3.  Is it justified to perform a bone marrow biopsy examination in sustained erythrocytosis?

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

Review 4.  Essential thrombocythemia.

Authors:  Jean B Brière
Journal:  Orphanet J Rare Dis       Date:  2007-01-08       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.